TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12358171

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 236

Group type: COMPARATOR
Intervention: Women
Number of subjects: 236
Study: 10354963

Group type: EXPERIMENTAL
Intervention: lamivudine/zidovudine combination tablet after an overnight fast
Number of subjects: 24

Group type: COMPARATOR
Intervention: lamivudine 150 mg tablet and zidovudine 300 mg tablet administered concurrently after an overnight fast
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: lamivudine/zidovudine combination tablet 5 minutes after a standardized high-fat breakfast
Number of subjects: 24
Study: 7796357

Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg twice daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Erythromycin 500 mg four times daily
Number of subjects: 40
Study: 2309640

Group type: EXPERIMENTAL
Intervention: Very-low-calorie diets (less than 500 kcal/d) with different compositions
Number of subjects: 5

Group type: COMPARATOR
Intervention: Conventional 1200-kcal/d hypocaloric diet
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Very-low-calorie diets (less than 500 kcal/d)
Number of subjects: 5
Study: 678769

Group type: EXPERIMENTAL
Intervention: Single dose of depot penicillin at the time of suture
Number of subjects: 285

Group type: COMPARATOR
Intervention: No antibiotic cover
Number of subjects: 285
Study: 31003515

Group type: EXPERIMENTAL
Intervention: Initial nutritional intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initial physical activity intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 27480573

Group type: EXPERIMENTAL
Intervention: Equicrestal implants (G1, n=28)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Subcrestal implants (G2, n=27)
Number of subjects: 55
Study: 26156901

Group type: EXPERIMENTAL
Intervention: Quetiapine (mean 500 mg/day)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Risperidone (mean 5.2 mg/day)
Number of subjects: 90
Study: 23339638

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV) with a Novalung R100 ventilator (Metran)
Number of subjects: 795

Group type: COMPARATOR
Intervention: Conventional ventilation (usual ventilatory care)
Number of subjects: 795
Study: 20931220

Group type: EXPERIMENTAL
Intervention: Plyometric training
Number of subjects: 19
Study: 19469706

Group type: EXPERIMENTAL
Intervention: sorivudine cream
Number of subjects: 25

Group type: COMPARATOR
Intervention: placebo cream
Number of subjects: 25
Study: 16753975

Group type: EXPERIMENTAL
Intervention: High frequency chest wall oscillation (HFCWO) administered twice-daily for 15 min duration plus standard care
Number of subjects: 9

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High frequency chest wall oscillation (HFCWO)
Number of subjects: 9
Study: 15249525

Group type: EXPERIMENTAL
Intervention: Prompt access to physiotherapy (physiotherapist clinics established in primary care)
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Prompt access to physiotherapy
Number of subjects: 614
Study: 11359031

Group type: EXPERIMENTAL
Intervention: Centrally obese subjects (WHR >=0.81 for women and >=0.92 for men)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Peripherally obese subjects (WHR <0.81 for women and <0.92 for men)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Controls (BMI <27.8 for men and <27.3 for women)
Number of subjects: 77
Study: 9286741

Group type: EXPERIMENTAL
Intervention: Vitamin C (1,000 mg/day for 8 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8356859

Group type: EXPERIMENTAL
Intervention: Epidural analgesia with 20 ml of 0.125% bupivacaine and 2 mg of morphine administered epidurally about 30 min before the end of the operation
Number of subjects: 14

Group type: COMPARATOR
Intervention: General anesthesia alone with nitrous oxide, oxygen and enflurane (control group)
Number of subjects: 14
Study: 2887190

Group type: EXPERIMENTAL
Intervention: Atenolol 50-100 mg day-1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Labetalol 200-800 mg day-1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pindolol 10-30 mg day-1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Captopril 25-100 mg day-1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All four drugs
Number of subjects: 40
Study: 30382819

Group type: EXPERIMENTAL
Intervention: Open lung approach (OLA) with PEEP titration, external PEEP selected was 6 ± 0.8 cmH2O.
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Open lung approach (OLA) with PEEP titration.
Number of subjects: 13
Study: 27965838

Group type: EXPERIMENTAL
Intervention: Immediate tumor resection after stopping chemotherapy
Number of subjects: 84

Group type: COMPARATOR
Intervention: Completion of chemotherapy before surgery
Number of subjects: 84
Study: 24610807

Group type: EXPERIMENTAL
Intervention: ICD-CRT
Number of subjects: 682
Study: 23012311

Group type: EXPERIMENTAL
Intervention: Feedback letter intervention sent to 72 alcohol outlets
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group (74 outlets)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Interviews with outlets regarding handling of the intervention
Number of subjects: 146
Study: 20806998

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Sham electro-acupuncture (SEA)
Number of subjects: 55
Study: 18975535

Group type: EXPERIMENTAL
Intervention: Continuous infusion of ketamine (300-400 microg x kg(‐1) x hr(‐))
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (control) group
Number of subjects: 40
Study: 16875724

Group type: EXPERIMENTAL
Intervention: Exercise Prescription Model (EPM) - 30-minute continuous activity, 3-4 days per week
Number of subjects: 50

Group type: COMPARATOR
Intervention: Lifestyle group (LIFE) - 6-minute activity, 5 times per day, 4-5 days per week
Number of subjects: 50
Study: 12954465

Group type: EXPERIMENTAL
Intervention: Mobile Geriatric Assessment Team (MGAT)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Barthel Index
Number of subjects: 265

Group type: COMPARATOR
Intervention: Physical Self‐Maintenance Scale
Number of subjects: 265

Group type: COMPARATOR
Intervention: Instrumental Activities of Daily Living
Number of subjects: 265

Group type: COMPARATOR
Intervention: modified Spitzer Quality of Life Index
Number of subjects: 265
Study: 10812039

Group type: EXPERIMENTAL
Intervention: 0.5 mol/L sodium lactate infused over 20 min
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo infused over 20 min
Number of subjects: 0
Study: 9017056

Group type: EXPERIMENTAL
Intervention: Amvisc with aspiration and topical timolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timolol (Blocadren)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healon
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amvisc without aspiration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healon with aspiration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amvisc without timolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healon without timolol
Number of subjects: 0
Study: 1517815

Group type: EXPERIMENTAL
Intervention: Intra-arterial cisplatin (CDDP)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Intravenous cisplatin (CDDP)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Both groups (IA CDDP and IV CDDP)
Number of subjects: 79
Study: 6576623

Group type: EXPERIMENTAL
Intervention: Standardized breakfast stimulation
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: i.v. glucose + i.v. arginine stimulation
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 24-hour profile of serum C-peptide
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Urinary C-peptide
Number of subjects: 49
Study: 28714759

Group type: EXPERIMENTAL
Intervention: Kinesio taping group (KTG)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Rigid taping group (RTG)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo group (placebo kinesio taping)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (no taping)
Number of subjects: 86
Study: 30323559

Group type: EXPERIMENTAL
Intervention: Butorphanol
Number of subjects: 942
Study: 27091603

Group type: EXPERIMENTAL
Intervention: CHILE intervention
Number of subjects: 655

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 655
Study: 24531687

Group type: EXPERIMENTAL
Intervention: PG201 600 mg
Number of subjects: 309

Group type: COMPARATOR
Intervention: Celecoxib 200 mg
Number of subjects: 309
Study: 22259009

Group type: EXPERIMENTAL
Intervention: Regadenoson 0.4 mg intravenous injection
Number of subjects: 432

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 432
Study: 19473285

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg taken once daily
Number of subjects: 342

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 342
Study: 17891597

Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol 20 microg plus levonorgestrel 100 microg (EE20/LNG100)
Number of subjects: 78

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 78
Study: 15365570

Group type: EXPERIMENTAL
Intervention: Irinotecan monotherapy (350 mg m(‐2) once every 3 weeks)
Number of subjects: 339
Study: 11239541

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg; n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Continuous combined 17-beta-estradiol (2 mg) and norethindrone acetate (1 mg; n = 50)
Number of subjects: 100
Study: 9737353

Group type: EXPERIMENTAL
Intervention: prednisolone, 10 mg twice daily
Number of subjects: 48
Study: 7508194

Group type: EXPERIMENTAL
Intervention: Human galanin (500 micrograms) in saline (100 ml)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline (100 ml)
Number of subjects: 6
Study: 2727326

Group type: EXPERIMENTAL
Intervention: Open mouth breathing
Number of subjects: 78

Group type: COMPARATOR
Intervention: Tachypnea
Number of subjects: 78

Group type: COMPARATOR
Intervention: Hyperpnea
Number of subjects: 78

Group type: COMPARATOR
Intervention: Combination of breathing patterns
Number of subjects: 78
Study: 30099398

Group type: EXPERIMENTAL
Intervention: Case method learning (CM)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Traditional lectures (TL)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Reference group (no CME)
Number of subjects: 255
Study: 26220762

Group type: COMPARATOR
Intervention: Alfaxalone
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Alfaxalone-dexmedetomidine (0.3 mg 100 mL(‐1))
Number of subjects: 14
Study: 25660434

Group type: EXPERIMENTAL
Intervention: Duloxetine 60-120 mg/d
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 23982301

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 73

Group type: COMPARATOR
Intervention: Midazolam (active placebo)
Number of subjects: 73
Study: 19854114

Group type: EXPERIMENTAL
Intervention: Accelerated partial breast irradiation (APBI)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Presence of positive axillary node(s)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Presence of estrogen receptor (ER) negative tumor
Number of subjects: 204
Study: 18435852

Group type: EXPERIMENTAL
Intervention: Rosiglitazone added to metformin
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: Rosiglitazone added to sulfonylureas
Number of subjects: 759
Study: 17158431

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 26

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 26
Study: 14722364

Group type: EXPERIMENTAL
Intervention: Nutrition education
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Iron supplementation (20 mg elemental iron)
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Nutrition education with supplementation (20 mg elemental iron)
Number of subjects: 451

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 451
Study: 10745678

Group type: EXPERIMENTAL
Intervention: 750 mL black currant/apple juice (1:1)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 1000 mL black currant/apple juice (1:1)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 1500 mL black currant/apple juice (1:1)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Juice intervention (all doses)
Number of subjects: 5
Study: 8792117

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 86
Study: 1291401

Group type: EXPERIMENTAL
Intervention: trimethoprim/sulfamethoxazole (TMP/SMX)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: clioquinol
Number of subjects: 2

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: enoxacin
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: TMP/SMX
Number of subjects: 2
Study: 3881960

Group type: EXPERIMENTAL
Intervention: Combined estrogen-androgen drug
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Androgen alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Estrogen alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31036708

Group type: COMPARATOR
Intervention: Hip prosthesis constructs (various brands)
Number of subjects: 4442
Study: 29790266

Group type: EXPERIMENTAL
Intervention: Oral clindamycin 300 mg twice daily for 5 days
Number of subjects: 1727

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1727
Study: 26600073

Group type: EXPERIMENTAL
Intervention: Seven days a week individual therapy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Five days a week circuit class therapy
Number of subjects: 10
Study: 24887381

Group type: EXPERIMENTAL
Intervention: Haplo‐HSCT
Number of subjects: 410

Group type: COMPARATOR
Intervention: UCBT
Number of subjects: 410
Study: 22305998

Group type: EXPERIMENTAL
Intervention: aliskiren/amlodipine/HCTZ 300/10/25 mg
Number of subjects: 412

Group type: COMPARATOR
Intervention: aliskiren/amlodipine 300/10 mg
Number of subjects: 412
Study: 19806530

Group type: EXPERIMENTAL
Intervention: Amnioinfusion (AI) for the prevention of MAS
Number of subjects: 0
Study: 18363895

Group type: EXPERIMENTAL
Intervention: 10 mg clevudine once daily for 12 weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 30 mg clevudine once daily for 12 weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 50 mg clevudine once daily for 12 weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Clevudine overall
Number of subjects: 31
Study: 16240065

Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation using an oral sodium phosphate solution and rectal enema on the morning of the procedure.
Number of subjects: 101

Group type: COMPARATOR
Intervention: No bowel preparation (control group).
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation group.
Number of subjects: 101
Study: 11884902

Group type: EXPERIMENTAL
Intervention: Proactive intervention
Number of subjects: 6176

Group type: EXPERIMENTAL
Intervention: Passive intervention
Number of subjects: 6176

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 6176
Study: 9505096

Group type: EXPERIMENTAL
Intervention: Standard intervention (HIV risk reduction education, HIV testing with pretest and posttest counseling, training in condom use and needle cleaning)
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Enhanced intervention (additional information on STD risk reduction)
Number of subjects: 684

Group type: COMPARATOR
Intervention: Standard intervention
Number of subjects: 684

Group type: COMPARATOR
Intervention: Enhanced intervention
Number of subjects: 684
Study: 7796353

Group type: EXPERIMENTAL
Intervention: Osteoporotic subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonosteoporotic subjects
Number of subjects: 0
Study: 2195013

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 522637

Group type: EXPERIMENTAL
Intervention: Oxprenolol 40 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 29185780

Group type: EXPERIMENTAL
Intervention: Saffron capsules (15 mg/twice daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 28864400

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 22
Study: 26445158

Group type: EXPERIMENTAL
Intervention: Prescribed exercise intensity at 40% of one-repetition maximum (1RM)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Prescribed exercise intensity at 60% of one-repetition maximum (1RM)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Prescribed exercise intensity at 80% of one-repetition maximum (1RM)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Self-selected intensity
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control condition without exercise
Number of subjects: 16
Study: 23926422

Group type: EXPERIMENTAL
Intervention: Quetiapine (25-100 mg/day, mean 67.6 mg/day)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Haloperidol (0.5-2.0 mg/day, mean 0.8 mg/day)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 52
Study: 21425514

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nerve stimulation guidance
Number of subjects: 100
Study: 18475003

Group type: EXPERIMENTAL
Intervention: Triple P Level 4 interventions
Number of subjects: 0
Study: 17198445

Group type: EXPERIMENTAL
Intervention: Pulse intravenous methylprednisolone (1000 mg for 4 days) plus cyclophosphamide (500 mg for 1 day)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Oral prednisolone (1-2 mg/kg/day for 28 days) plus azathioprine (1.5 mg/kg/day)
Number of subjects: 123
Study: 12749513

Group type: EXPERIMENTAL
Intervention: Dirithromycin 500 mg QD for 5 days
Number of subjects: 86

Group type: COMPARATOR
Intervention: Azithromycin 500 mg QD on day 1 and 250 mg QD on days 2 to 5
Number of subjects: 86
Study: 11136302

Group type: EXPERIMENTAL
Intervention: Wrist cuff during venous occlusion
Number of subjects: 8

Group type: COMPARATOR
Intervention: No wrist cuff during venous occlusion
Number of subjects: 8
Study: 9554155

Group type: EXPERIMENTAL
Intervention: Western blot method using 8 kDa antigenic fraction
Number of subjects: 47

Group type: COMPARATOR
Intervention: Indirect haemagglutination, immunoelectrophoresis, and ELISA
Number of subjects: 47
Study: 1316079

Group type: EXPERIMENTAL
Intervention: Once-daily 400 mg lomefloxacin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Twice-daily 400 mg lomefloxacin
Number of subjects: 100
Study: 2931232

Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg once a day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (1 tablet once a day)
Number of subjects: 20
Study: 29889058

Group type: EXPERIMENTAL
Intervention: FIFA 11+ training program for 12 weeks (five times per week)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Regular training (control group)
Number of subjects: 57
Study: 27598763

Group type: EXPERIMENTAL
Intervention: Celebrity images
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Peer images
Number of subjects: 138

Group type: COMPARATOR
Intervention: Travel images
Number of subjects: 138
Study: 24854041

Group type: EXPERIMENTAL
Intervention: Insulin pump (continuous subcutaneous insulin infusion [CSII])
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (RT)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Multiple daily injections (MDI)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Conventional self-monitoring of blood glucose (SMBG)
Number of subjects: 96
Study: 21781200

Group type: EXPERIMENTAL
Intervention: Gum chewing exercise (twice daily for 5 minutes over 4 weeks)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (no gum chewing)
Number of subjects: 98
Study: 20643366

Group type: EXPERIMENTAL
Intervention: Auricular acupressure to six auricular acupoints
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group without acupressure
Number of subjects: 94

Group type: COMPARATOR
Intervention: Both groups (experimental and control)
Number of subjects: 94
Study: 18626263

Group type: EXPERIMENTAL
Intervention: 5 g of 1% testosterone gel (Testogel)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 16034518

Group type: EXPERIMENTAL
Intervention: Rebeccamycin analogue (RA) 500 mg/m(2) as a 1 hr infusion repeated every 3 weeks (Arm A)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Rebeccamycin analogue (RA) 140 mg/m(2)/day x 5 days repeated every 3 weeks (Arm B)
Number of subjects: 42
Study: 12477578

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg/day
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 10539878

Group type: EXPERIMENTAL
Intervention: Preoperative transfusion regimen (conservative to bring hemoglobin concentration to between 9 and 11 g/dl)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Preoperative transfusion regimen (aggressive to lower hemoglobin S level to 30%)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Hip replacements
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Hip coring procedures
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Overall perioperative care guidelines compliance
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Transfusion complications
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Surgical complications after hip replacements
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Deaths following surgery
Number of subjects: 118
Study: 8955454

Group type: EXPERIMENTAL
Intervention: Combination of nalidixic acid and metronidazole
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Metronidazole alone
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study: 2011075

Group type: EXPERIMENTAL
Intervention: High protein diet (23% of energy as protein)
Number of subjects: 10
Study: 7134028

Group type: EXPERIMENTAL
Intervention: Ceruletide 120 ng/kg b. wt/hr
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ceruletide 60 ng/kg b. wt/hr
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 24
Study: 31991898

Group type: EXPERIMENTAL
Intervention: High-dose omega-3 and omega-6 fatty acids supplementation with antioxidant vitamins (20 mL containing 810 mg Eicosapentaenoic acid, 4140 mg Docosahexaenoic acid, 1800 mg gamma-Linolenic acid, 3150 mg Linoleic acid, 0.6 mg vitamin A, 22 mg vitamin E, 760 mg pure γ-tocopherol)
Number of subjects: 46